Immunotherapy of HIV-infected patients with intermittent interleukin-2: Effects of cycle frequency and cycle duration on degree of CD4+ T-lymphocyte expansion

Clinical Immunology

Volumn 99, Issue 1, 2001, Pages 30-42

  Miller, Kirk D ^a   Spooner, Katherine ^a,c   Herpin, Betsey R ^b   Rock Kress, Diane ^a   Metcalf, Julia A ^b   Davey Jr , Richard T ^b   Falloon, Judith ^b   Kovacs, Joseph A ^a   Polis, Michael A ^b   Walker, Robert E ^b   Masur, Henry ^a   Lane, H Clifford ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Anti HIV agents; CD4 lymphocyte count; HIV infection; Interleukin 2

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR; RECOMBINANT INTERLEUKIN 2; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; LYMPHOCYTE COUNT; MALE; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; VIRUS LOAD;

EID: 0035047644     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.2001.5001     Document Type: Article

References (44)

1. HIV-protease inhibitors
2. HIV/AIDS in 1998 - Gaining the upper hand?
3. Antiretroviral therapy for HIV infection: Promises and problems
4. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
5. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
6. HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy
7. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
8. Residual HIV-1 disease in the era of highly active antiretroviral therapy
9. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
10. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
11. Recombinant interleukin-2-induced polyclonal proliferation of in vitro unstimulated human peripheral blood lymphocytes
12. Interleukin-2: Inception, impact, and implications
13. Immune-based therapies for treatment of HIV infection
14. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome
15. Human recombinant interleukin-2 partly reconstitutes deficient in-vitro immune responses of lymphocytes from patients with AIDS
16. Interleukin 2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a gamma-interferon-independent mechanism
17. Effects in systemic in vivo interleukin-2 (IL-2) reconstitution in patients with acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC) on phenotypes and functions of peripheral blood mononuclear cells (PBMC)
18. Use of interleukin-2 in patients with acquired immunodeficiency syndrome
19. Preliminary clinical observations with recombinant interleukin-2 in patients with AIDS or LAS
20. Intralymphatic interleukin 2 treatment in patients with acquired immunodeficiency syndrome: Preliminary experience in three cases
21. A phase I/II trial of recombinant interleukin-2 in AIDS/ARC: Alterations of phenotypes of peripheral blood mononuclear cells
22. Intralymphatic interleukin-2 treatment of hemophiliac AIDS patient with defective interleukin-2 production
23. Abnormalities of interleukin 2 receptor expression associated with decreased antigen-induced lymphocyte proliferation in patients with AIDS and related disorders
24. Therapy of acquired immune deficiency syndrome with recombinant interleukin-2
25. A phase I study of interferon-alpha 2b in combination with interleukin-2 in patients with human immunodeficiency virus infection
26. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study
27. Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV+ subjects
28. A phase I study of subcutaneous recombinant interleukin-2 in patients with advanced HIV disease while on zidovudine
29. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons
30. A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therpy for early human immunodeficiency virus type 1 infection
31. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus
32. Outpatient continuous intravenous interleukin-2 or subcutaneous polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: A randomized, controlled, multicenter study
33. Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients
34. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiencyvirus infection
35. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: A randomised controlled trial
36. Immunologic evaluation of patients with human immunodeficiency virus infection
37. 1994 Revised guidelines for the performance of CD4+ T-cell determinations in persons with human immunodeficiency virus (HIV) infections. Centers for Disease Control and Prevention
38. Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma
39. Pharmacokinetics and pharmacodynamics of subcutaneous interleukin-2 in HIV-infected patients
40. Duration of Proleukin IL-2 therapy is more important than total dose in achieving CD4 expansion
41. Interleukin-2 induced immune effects in Human Immunodeficiency Virus-infected patients receiving in-termittent interleukin-2 immunotherapy
42. A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand
43. 3
44. Meta-analysis of three randomised, controlled trials of interleukin-2 therapy in adult HIV disease